Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

wockhardt uk ltd - sulfadiazine - oral tablet - 500mg

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - sulfadiazine - oral tablet - 500mg

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - sulfadiazine - oral tablet - 500mg

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - sulfadiazine - oral tablet - 500mg

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

ennogen healthcare ltd - sulfadiazine - oral tablet - 500mg

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

lake erie medical & surgical supply dba quality care products llc - silver sulfadiazine (unii: w46jy43ejr) (silver sulfadiazine - unii:w46jy43ejr) - silver sulfadiazine 10 g in 1000 g - silver sulfadiazine 1% cream is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second- and third-degree burns. silver sulfadiazine 1% cream is contraindicated in patients who are hypersensitive to silver sulfadiazine or any of the other ingredients in the preparation. because sulfonamide therapy is known to increase the possibility of kernicterus, silver sulfadiazine 1% cream should not be used on pregnant women approaching or at term, on premature infants, or on newborn infants during the first 2 months of life.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

keltman pharmaceuticals inc. - silver sulfadiazine (unii: w46jy43ejr) (silver sulfadiazine - unii:w46jy43ejr) - silver sulfadiazine 10 mg in 1 g - silver sulfadiazine 1% cream is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second- and third-degree burns. silver sulfadiazine 1% cream is contraindicated in patients who are hypersensitive to silver sulfadiazine or any of the other ingredients in the preparation. because sulfonamide therapy is known to increase the possibility of kernicterus, silver sulfadiazine 1% cream should not be used on pregnant women approaching or at term, on premature infants, or on newborn infants during the first 2 months of life.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

pegasus laboratories, inc - sulfadiazine sodium (unii: 84cs1p306f) (sulfadiazine - unii:0n7609k889), pyrimethamine (unii: z3614qox8w) (pyrimethamine - unii:z3614qox8w) - sulfadiazine 250 mg in 1 ml - rebalance antiprotozoal oral suspension is indicated for the treatment of horses with equine protozoal myeloencephalitis (epm) caused by sarcocystis neurona . the use of rebalance antiprotozoal oral suspension in contraindicated in horses with known hypersensitivity to sulfonamide drugs or pyrimethamine.

Prantsusmaa - prantsuse - ANSES (Agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et du travail)

ceva sante animale - sulfadiazine sodique, triméthoprime - prémélange médicamenteux - anti-infectieux à usage systémique, association d'un sulfamide et de triméthoprime - porcins

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - silver sulfadiazine (unii: w46jy43ejr) (sulfadiazine - unii:0n7609k889) -      silver sulfadiazine cream, usp 1% is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns.      silver sulfadiazine cream, usp 1% is contraindicated in patients who are hypersensitive to silver sulfadiazine or any of the other ingredients in the preparation.      because sulfonamide therapy is known to increase the possibility of kernicterus, silver sulfadiazine cream, usp 1% should not be used on pregnant women approaching or at term, on premature infants, or on newborn infants during the first 2 months of life.      geriatric use. of the total number of subjects in clinical studies of silver sulfadiazine cream, usp 1% seven percent were 65 years of age and over. no overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater